Fast and effective therapeutic debridement of burn injuries and chronic ulcers.
Burn wounds and chronic wounds like the well known open leg and diabetic foot are a burden to the patient and the health care system. Healing is often hampered by eschar and necrotic tissue. Removal is called debridement, to enable the wound to heal. There are multiple ways of debridement, most of which are expensive, little effective, very unpleasant and painful.
The developmental prescription product of SERDA therapeutics is expected to bring fast and effective wound debridement, ease of use, high stability and low-moderate irritation potential, based on the preclinical data. It contains a proteolytic enzyme, which selectively digests and removes the necrotic tissue and eschar from the wound. This way the wound has the possibility to heal.